A cytokine inhibition experiment in lung cancer A549 cells, a human lung epithelial cell line that has been generally used to evaluate the ability of glucocorticoids to inhibit the secretion of secondary inflammatory cytokines on primary pro-inflammatory cytokine stimulation [27], showed that VSGC12 has higher potency than VSG22, but a lower potency than FF, in inhibiting the release of IL-6 (Figure 1e), similar to what we found in the reporter assays. This evidence concerns the gene IL6 and lung carcinoma.